Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Consolidated Net Income: 2012-2024

Historic Consolidated Net Income for Coherus Oncology (CHRS) over the last 13 years, with Dec 2024 value amounting to $28.5 million.

  • Coherus Oncology's Consolidated Net Income fell 75.61% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $540.3 million, marking a year-over-year increase of 217.73%. This contributed to the annual value of $28.5 million for FY2024, which is 111.98% up from last year.
  • As of FY2024, Coherus Oncology's Consolidated Net Income stood at $28.5 million, which was up 111.98% from -$237.9 million recorded in FY2023.
  • Coherus Oncology's 5-year Consolidated Net Income high stood at $132.2 million for FY2020, and its period low was -$291.8 million during FY2022.
  • Over the past 3 years, Coherus Oncology's median Consolidated Net Income value was -$237.9 million (recorded in 2023), while the average stood at -$167.0 million.
  • In the last 5 years, Coherus Oncology's Consolidated Net Income plummeted by 317.16% in 2021 and then soared by 111.98% in 2024.
  • Over the past 5 years, Coherus Oncology's Consolidated Net Income (Yearly) stood at $132.2 million in 2020, then slumped by 317.16% to -$287.1 million in 2021, then declined by 1.62% to -$291.8 million in 2022, then grew by 18.46% to -$237.9 million in 2023, then spiked by 111.98% to $28.5 million in 2024.